This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.
Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $467.28, indicating a -1.35% shift from the previous trading day.
Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
by Zacks Equity Research
Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Vertex Pharmaceuticals (VRTX) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $475.79, signifying a -1.19% move from its prior day's close.
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Why Is Vertex (VRTX) Up 15.8% Since Last Earnings Report?
by Zacks Equity Research
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Health Care Stocks Show Relative Strength as S&P 500 Stalls
by Bryan Hayes
Several stocks are breaking out and trading near all-time highs.
Why Vertex Pharmaceuticals (VRTX) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Vertex (VRTX) Outperforms Industry on Rapid Pipeline Progress
by Zacks Equity Research
While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
by Zacks Equity Research
bluebird (BLUE) beats sales estimates in the first quarter on increased Zynteglo product revenues. The company is on track with the ongoing launch of its gene therapies.
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
by Zacks Equity Research
Editas (EDIT) reports weaker-than-expected first-quarter 2024 results as both earnings and revenues fall shy of estimates. Shares fall.
CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.
Vertex (VRTX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Vertex's (VRTX) Q1 Earnings Beat, Trikafta Drives Sales
by Zacks Equity Research
Vertex's (VRTX) first-quarter earnings and revenues surpass estimates. Higher sales of Trikafta/Kaftrio in U.S. and ex-U.S. markets drive the top line.
Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of 16.10% and 5.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to the first sales numbers of its newly approved gene therapy, Casgevy.
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $400.16, representing a -0.49% change from its previous close.
Will Arcus Biosciences, Inc. (RCUS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Unveiling Vertex (VRTX) Q1 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Vertex (VRTX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Vertex's (VRTX) revenues in the first quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.